Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + fruquintinib + albumin-bound paclitaxel for second-line advanced HER2-negative gastric cancer
ChiCTR2300076150Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab, fruquintinib and paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
sintilimabfruquintinibpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300076150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076150.